https://simplecast.com The Results Are In from Quest Diagnostics® Physicians routinely diagnose and treat acute and chronic conditions across multiple clinical areas. Whether it’s a condition studied for decades or an emerging infection, comprehensive diagnostic testing is enabling faster and more effective care to drive better patient outcomes. In fact, most medical decisions are based at least partly on lab testing! On The Results Are In from Quest Diagnostics®, we are joined by diagnostics industry leaders who support providers in optimizing care pathways for their patients. From the latest in cutting-edge research to the real-world impact of diagnostic testing on treatment journeys, The Results Are In features can’t-miss stories for those wanting to stay in the know about the latest innovations in laboratory diagnostics. 2025 Quest Diagnostics® en Wed, 4 Mar 2026 05:00:00 +0000 Wed, 4 Mar 2026 05:00:12 +0000 https://the-results-are-in.simplecast.com The Results Are In from Quest Diagnostics® https://image.simplecastcdn.com/images/748ca0d2-56fa-423c-8807-519c7b1cbe07/f536d6cf-9bb6-4131-9bf9-095750c49f07/3000x3000/02-show-20art-v2-quest-20idi-the-20results-20are-20in-option01.jpg?aid=rss_feed https://the-results-are-in.simplecast.com episodic Physicians routinely diagnose and treat acute and chronic conditions across multiple clinical areas. Whether it’s a condition studied for decades or an emerging infection, comprehensive diagnostic testing is enabling faster and more effective care to drive better patient outcomes. In fact, most medical decisions are based at least partly on lab testing! On The Results Are In from Quest Diagnostics®, we are joined by diagnostics industry leaders who support providers in optimizing care pathways for their patients. From the latest in cutting-edge research to the real-world impact of diagnostic testing on treatment journeys, The Results Are In features can’t-miss stories for those wanting to stay in the know about the latest innovations in laboratory diagnostics. Quest Diagnostics® false https://feeds.simplecast.com/m_q_Mnsw Quest Diagnostics® stories@amazemedialabs.com 649b1aeb-4bdb-411d-bf88-715c9c5ffbd6 Exocrine pancreatic insufficiency: Symptoms, risk factors, and the value of pancreatic elastase testing Exocrine pancreatic insufficiency (EPI) is an underrecognized but clinically significant condition that can lead to malnutrition, weight loss, and long-term complications if left undiagnosed. Fortunately, there's a noninvasive and highly specific test that can help clinicians take the guesswork out of diagnosis.

In this episode of The Results Are In, host Jen Jenkins speaks with Dr Elif Nahas, Associate Director of Pathology and Chair of the Gastrointestinal and Liver Resource Committee at Quest Diagnostics. Dr Nahas explains what EPI is, the most common symptoms, and which patients are at highest risk. She also outlines how pancreatic elastase testing works, why it’s reliable even for patients already on pancreatic enzyme replacement therapy, and how to interpret test results accurately.

Whether you're a primary care provider or a GI specialist, this episode offers clear insights into why EPI should be on your diagnostic radar and how early identification and treatment can significantly improve patient outcomes.

Follow Us

Twitter @QuestDX 
Facebook @QuestDiagnostics

Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Abbreviations used in episode:

EPI: Exocrine pancreatic insufficiency

AGA: American Gastroenterological Association

References mentioned in episode: 

  1. Quest Diagnostics Test Directory – Pancreatic Elastase-1, Fecal:
    https://testdirectory.questdiagnostics.com/test/test-detail/14693/pancreatic-elastase-1?cc=MASTER
  2. American Gastroenterological Association (AGA):
    https://gastro.org

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Wed, 4 Mar 2026 05:00:00 +0000 stories@amazemedialabs.com (Jen Jenkins, Dr Elif Nahas) https://the-results-are-in.simplecast.com/episodes/exocrine-pancreatic-insufficiency-symptoms-risk-factors-and-the-value-of-pancreatic-elastase-testing-yZnN29J8 Exocrine pancreatic insufficiency (EPI) is an underrecognized but clinically significant condition that can lead to malnutrition, weight loss, and long-term complications if left undiagnosed. Fortunately, there's a noninvasive and highly specific test that can help clinicians take the guesswork out of diagnosis.

In this episode of The Results Are In, host Jen Jenkins speaks with Dr Elif Nahas, Associate Director of Pathology and Chair of the Gastrointestinal and Liver Resource Committee at Quest Diagnostics. Dr Nahas explains what EPI is, the most common symptoms, and which patients are at highest risk. She also outlines how pancreatic elastase testing works, why it’s reliable even for patients already on pancreatic enzyme replacement therapy, and how to interpret test results accurately.

Whether you're a primary care provider or a GI specialist, this episode offers clear insights into why EPI should be on your diagnostic radar and how early identification and treatment can significantly improve patient outcomes.

Follow Us

Twitter @QuestDX 
Facebook @QuestDiagnostics

Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Abbreviations used in episode:

EPI: Exocrine pancreatic insufficiency

AGA: American Gastroenterological Association

References mentioned in episode: 

  1. Quest Diagnostics Test Directory – Pancreatic Elastase-1, Fecal:
    https://testdirectory.questdiagnostics.com/test/test-detail/14693/pancreatic-elastase-1?cc=MASTER
  2. American Gastroenterological Association (AGA):
    https://gastro.org

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Exocrine pancreatic insufficiency: Symptoms, risk factors, and the value of pancreatic elastase testing Jen Jenkins, Dr Elif Nahas 00:10:07 Dr. Elif Nahas breaks down EPI symptoms, risk factors, and why pancreatic elastase testing supports timely, effective diagnosis and care. Dr. Elif Nahas breaks down EPI symptoms, risk factors, and why pancreatic elastase testing supports timely, effective diagnosis and care. false full 7 f0fca1c8-9947-46d6-a55d-746752b0ad4c Discovering Prenatal Genetics The evolution of prenatal genetics is transforming care by supporting clarity, confidence, and a patient-centric approach.

In this episode of The Results Are In by Quest Diagnostics, host Lisa Demers is joined by Paul Kezmarsky, Director of Strategy & Solutions in Genetics at Quest. A board-certified genetic counselor, Paul brings over a decade of experience across both clinical and laboratory settings, with a focus on expanding access to care.

They explore how prenatal genetic screening has evolved from the days of limited biochemical tests to today’s broader, pan-ethnic screening approaches. They break down how these tests work, what makes them clinically useful, and why clear results supported by expert guidance are essential for providers and their patients.

This episode offers a straightforward look at how prenatal genetics is reshaping pregnancy care, making it more proactive, inclusive, and actionable for providers everywhere.

Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Presented by Quest Diagnostics
www.questdiagnostics.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 6 Feb 2026 05:00:00 +0000 stories@amazemedialabs.com (Lisa Demers, Paul Kezmarsky) https://the-results-are-in.simplecast.com/episodes/discovering-prenatal-genetics-BAyD33NQ The evolution of prenatal genetics is transforming care by supporting clarity, confidence, and a patient-centric approach.

In this episode of The Results Are In by Quest Diagnostics, host Lisa Demers is joined by Paul Kezmarsky, Director of Strategy & Solutions in Genetics at Quest. A board-certified genetic counselor, Paul brings over a decade of experience across both clinical and laboratory settings, with a focus on expanding access to care.

They explore how prenatal genetic screening has evolved from the days of limited biochemical tests to today’s broader, pan-ethnic screening approaches. They break down how these tests work, what makes them clinically useful, and why clear results supported by expert guidance are essential for providers and their patients.

This episode offers a straightforward look at how prenatal genetics is reshaping pregnancy care, making it more proactive, inclusive, and actionable for providers everywhere.

Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Presented by Quest Diagnostics
www.questdiagnostics.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Discovering Prenatal Genetics Lisa Demers, Paul Kezmarsky 00:11:15 Paul Kezmarsky shares how QNatal and QHerit support clinicians with actionable prenatal screening and expert-backed results. Paul Kezmarsky shares how QNatal and QHerit support clinicians with actionable prenatal screening and expert-backed results. false full 6 7f440cb7-9556-43c4-821f-c1b2f2ca3ed5 PFAS: Understanding the Risks and the Role of Testing Per- and polyfluoroalkyl substances (PFAS), often called “forever chemicals,” have made their way into drinking water, consumer products, and even our bodies. With potential health risks tied to exposure, PFAS have become one of the most pressing public health challenges today.

In this episode of The Results Are In from Quest Diagnostics, host Dr Jack Kain speaks with Dr. Sarah Bartock, National Science Director of Drug Monitoring & Toxicology at Quest. Together, they break down what PFAS are, how people are exposed, and the health conditions that have been linked to these chemicals. They also discuss how blood testing—including Quest’s PFAS 9 Panel—can help patients and providers better understand risk and make informed decisions about exposure reduction and health monitoring.

Listeners will also hear about emerging research into possible interventions, the limitations of current testing, and the broader challenges of addressing PFAS in the environment.

Don’t miss this important conversation that connects environmental science, preventive care, and clinical practice.

Follow Us

Twitter @QuestDX 
Facebook @QuestDiagnostics

Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Abbreviations used in episode:

NHANES: National Health and Nutrition Examination Survey 

NASEM: National Academies of Science, Engineering, and Medicine 

References mentioned in episode: 

  1. Møller JJ, Lyngberg AC, Hammer PEC, et al.. Substantial decrease of PFAS with anion exchange resin treatment - A clinical cross-over trial. Environ Int. 2024;185:108497. doi:10.1016/j.envint.2024.108497
  2. Ducatman A, Luster M, Fletcher T. Perfluoroalkyl substance excretion: Effects of organic anion-inhibiting and resin-binding drugs in a community setting. Environ Toxicol Pharmacol. 2021;85:103650. doi:10.1016/j.etap.2021.103650  
  3. Lindell AE, Grießhammer A, Michaelis L, et al. Human gut bacteria bioaccumulate per- and polyfluoroalkyl substances. Nat Microbiol. 2025;10(7):1630-1647.  
  4. Dzierlenga MW, Keast DR, Longnecker MP. The concentration of several perfluoroalkyl acids in serum appears to be reduced by dietary fiber. Environ Int. 2021;146:106292. doi:10.1016/j.envint.2020.106292
  5. Schlezinger JJ, Biswas K, Garcia A, Heiger-Bernays WJ, Bello D. An oat fiber intervention for reducing PFAS body burden: A pilot study in male C57Bl/6 J mice. Toxicol Appl Pharmacol.  2025;495:117188. doi:10.1016/j.taap.2024.117188
  6. Tian Y, Luan M, Zhang J, Yang H, Wang Y, Chen H. Associations of single and multiple perfluoroalkyl substances exposure with folate among adolescents in NHANES 2007-2010. Chemosphere. 2022;307(Pt 3):135995. doi:10.1016/j.chemosphere.2022.135995
  7. Zhang Y, Mustieles V, Wang YX, Sun Y, Agudelo J, et al.. Folate concentrations and serum perfluoroalkyl and polyfluoroalkyl substance concentrations in adolescents and adults in the USA (National Health and Nutrition Examination Study 2003-16): an observational study. Lancet Planet Health. 2023;7(6):e449-e458. doi:10.1016/S2542-5196(23)00088-8

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Wed, 5 Nov 2025 05:00:00 +0000 stories@amazemedialabs.com (Dr Jack Kain, Dr Sarah Bartock) https://the-results-are-in.simplecast.com/episodes/pfas-understanding-the-risks-and-the-role-of-testing-3EqqeeSe Per- and polyfluoroalkyl substances (PFAS), often called “forever chemicals,” have made their way into drinking water, consumer products, and even our bodies. With potential health risks tied to exposure, PFAS have become one of the most pressing public health challenges today.

In this episode of The Results Are In from Quest Diagnostics, host Dr Jack Kain speaks with Dr. Sarah Bartock, National Science Director of Drug Monitoring & Toxicology at Quest. Together, they break down what PFAS are, how people are exposed, and the health conditions that have been linked to these chemicals. They also discuss how blood testing—including Quest’s PFAS 9 Panel—can help patients and providers better understand risk and make informed decisions about exposure reduction and health monitoring.

Listeners will also hear about emerging research into possible interventions, the limitations of current testing, and the broader challenges of addressing PFAS in the environment.

Don’t miss this important conversation that connects environmental science, preventive care, and clinical practice.

Follow Us

Twitter @QuestDX 
Facebook @QuestDiagnostics

Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Abbreviations used in episode:

NHANES: National Health and Nutrition Examination Survey 

NASEM: National Academies of Science, Engineering, and Medicine 

References mentioned in episode: 

  1. Møller JJ, Lyngberg AC, Hammer PEC, et al.. Substantial decrease of PFAS with anion exchange resin treatment - A clinical cross-over trial. Environ Int. 2024;185:108497. doi:10.1016/j.envint.2024.108497
  2. Ducatman A, Luster M, Fletcher T. Perfluoroalkyl substance excretion: Effects of organic anion-inhibiting and resin-binding drugs in a community setting. Environ Toxicol Pharmacol. 2021;85:103650. doi:10.1016/j.etap.2021.103650  
  3. Lindell AE, Grießhammer A, Michaelis L, et al. Human gut bacteria bioaccumulate per- and polyfluoroalkyl substances. Nat Microbiol. 2025;10(7):1630-1647.  
  4. Dzierlenga MW, Keast DR, Longnecker MP. The concentration of several perfluoroalkyl acids in serum appears to be reduced by dietary fiber. Environ Int. 2021;146:106292. doi:10.1016/j.envint.2020.106292
  5. Schlezinger JJ, Biswas K, Garcia A, Heiger-Bernays WJ, Bello D. An oat fiber intervention for reducing PFAS body burden: A pilot study in male C57Bl/6 J mice. Toxicol Appl Pharmacol.  2025;495:117188. doi:10.1016/j.taap.2024.117188
  6. Tian Y, Luan M, Zhang J, Yang H, Wang Y, Chen H. Associations of single and multiple perfluoroalkyl substances exposure with folate among adolescents in NHANES 2007-2010. Chemosphere. 2022;307(Pt 3):135995. doi:10.1016/j.chemosphere.2022.135995
  7. Zhang Y, Mustieles V, Wang YX, Sun Y, Agudelo J, et al.. Folate concentrations and serum perfluoroalkyl and polyfluoroalkyl substance concentrations in adolescents and adults in the USA (National Health and Nutrition Examination Study 2003-16): an observational study. Lancet Planet Health. 2023;7(6):e449-e458. doi:10.1016/S2542-5196(23)00088-8

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> PFAS: Understanding the Risks and the Role of Testing Dr Jack Kain, Dr Sarah Bartock 00:14:18 Dr. Sarah Bartock explains PFAS exposure, health risks, and how Quest’s PFAS 9 Panel can support patient care. Dr. Sarah Bartock explains PFAS exposure, health risks, and how Quest’s PFAS 9 Panel can support patient care. false full 5 7a967906-8d23-4df3-b18d-cb464b0ab040 Screening is the First Line of Defense: Testing for Hepatitis B, Hepatitis C, & HIV In this episode of Results Are In by Quest Diagnostics, Jen Jenkins is joined by Dr. Meghan W. Starolis, Senior Science Director of Infectious Disease at Quest Diagnostics, to discuss the importance of universal screening for hepatitis B, hepatitis C, and HIV. 

Dr. Starolis explains the CDC’s latest recommendations, the real-world impact of co-infections, and why regular testing is critical even for patients without symptoms. She also breaks down how Quest supports clinicians with tools like the HBV Triple Screen panel, which simplifies complex interpretations, and highlights recent innovations in HIV testing, including updated algorithms and clearer reporting for providers. Listeners will also gain insights into what an HIV “blip” means and how Quest is addressing provider feedback to improve patient care.

This episode is essential for healthcare professionals and patients alike who want to better understand why screening is the first step in prevention, care, and improved outcomes.

Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Presented by Quest Diagnostics
www.questdiagnostics.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 12 Sep 2025 04:00:00 +0000 stories@amazemedialabs.com (Jen Jenkins, Meghan W. Starolis) https://the-results-are-in.simplecast.com/episodes/screening-is-the-first-line-of-defense-testing-for-hepatitis-b-hepatitis-c-hiv-umWyIHsv In this episode of Results Are In by Quest Diagnostics, Jen Jenkins is joined by Dr. Meghan W. Starolis, Senior Science Director of Infectious Disease at Quest Diagnostics, to discuss the importance of universal screening for hepatitis B, hepatitis C, and HIV. 

Dr. Starolis explains the CDC’s latest recommendations, the real-world impact of co-infections, and why regular testing is critical even for patients without symptoms. She also breaks down how Quest supports clinicians with tools like the HBV Triple Screen panel, which simplifies complex interpretations, and highlights recent innovations in HIV testing, including updated algorithms and clearer reporting for providers. Listeners will also gain insights into what an HIV “blip” means and how Quest is addressing provider feedback to improve patient care.

This episode is essential for healthcare professionals and patients alike who want to better understand why screening is the first step in prevention, care, and improved outcomes.

Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Presented by Quest Diagnostics
www.questdiagnostics.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Screening is the First Line of Defense: Testing for Hepatitis B, Hepatitis C, & HIV Jen Jenkins, Meghan W. Starolis 00:18:57 Dr. Meghan Starolis explains why universal and risk-based screenings for Hepatitis B, Hepatitis C, and HIV are essential for better patient care. Dr. Meghan Starolis explains why universal and risk-based screenings for Hepatitis B, Hepatitis C, and HIV are essential for better patient care. false full 4 de4627fa-a0a9-493c-8946-cb19ed5dfe5f Enhancing Cancer Treatment Decisions with Ultrasensitive MRD Testing Across oncology care, clinicians are facing a growing demand for precision tools that go beyond standard imaging and protein biomarkers. In this episode of Results Are In by Quest Diagnostics, host Jesus Izaguirre-Carbonell welcomes Dr. Thomas P. Slavin Jr., Chief Clinical Officer of Molecular Oncology and Medical Director for Haystack MRD at Quest, for a focused conversation on minimal residual disease (MRD) testing.

Dr. Slavin walks through how ultrasensitive ctDNA detection is changing the game for treatment monitoring, especially in perisurgical and surveillance settings. He explains the science behind circulating tumor DNA, how MRD testing is helping avoid unnecessary chemotherapy, and what makes certain tests stand out in terms of sensitivity and access. The episode also highlights real clinical examples and emerging evidence that show how MRD testing is guiding decisions and reducing overtreatment.

This is a practical listen for clinicians, researchers, and anyone interested in the latest tools transforming cancer management from reactive to proactive.

Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Presented by Quest Diagnostics

www.questdiagnostics.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Tue, 8 Jul 2025 04:00:00 +0000 stories@amazemedialabs.com (Jesus Izaguirre-Carbonell, Dr. Thomas P. Slavin Jr) https://the-results-are-in.simplecast.com/episodes/enhancing-cancer-treatment-decisions-with-ultrasensitive-mrd-testing-TjEAgbEV Across oncology care, clinicians are facing a growing demand for precision tools that go beyond standard imaging and protein biomarkers. In this episode of Results Are In by Quest Diagnostics, host Jesus Izaguirre-Carbonell welcomes Dr. Thomas P. Slavin Jr., Chief Clinical Officer of Molecular Oncology and Medical Director for Haystack MRD at Quest, for a focused conversation on minimal residual disease (MRD) testing.

Dr. Slavin walks through how ultrasensitive ctDNA detection is changing the game for treatment monitoring, especially in perisurgical and surveillance settings. He explains the science behind circulating tumor DNA, how MRD testing is helping avoid unnecessary chemotherapy, and what makes certain tests stand out in terms of sensitivity and access. The episode also highlights real clinical examples and emerging evidence that show how MRD testing is guiding decisions and reducing overtreatment.

This is a practical listen for clinicians, researchers, and anyone interested in the latest tools transforming cancer management from reactive to proactive.

Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Presented by Quest Diagnostics

www.questdiagnostics.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Enhancing Cancer Treatment Decisions with Ultrasensitive MRD Testing Jesus Izaguirre-Carbonell, Dr. Thomas P. Slavin Jr 00:19:57 Dr. Thomas Slavin breaks down how ultrasensitive MRD testing supports better cancer treatment decisions and enables earlier, more personalized interventions. Dr. Thomas Slavin breaks down how ultrasensitive MRD testing supports better cancer treatment decisions and enables earlier, more personalized interventions. false full 3 5da196fb-9735-4702-9bb9-45f49cc812d5 Novel Psychoactive Substances (NPS): A Dangerous, Widespread Public Health Issue In this episode of Results are In by Quest Diagnostics, Dr. Jack Kain joins Jason Suomala to explain the threat of novel psychoactive substances and how Quest's updated testing panel helps providers identify what's being used and treat patients with more confidence. 

They break down what providers need to know about NPS classes like designer benzodiazepines, fentanyl analogs, synthetic cannabinoids, and more. With real-world case studies and clinical insights, the discussion highlights why traditional drug testing often misses these compounds—and how Quest’s updated NPS panel helps providers detect risk and guide treatment with greater accuracy.

The episode also explores how the evolving drug landscape, fueled by counterfeit pills and illicit drug mixing, is increasing overdose risks across the country. Whether you're a healthcare professional, toxicologist, or public health advocate, this conversation will help you better understand what’s really showing up in patients’ systems and what to do about it.

Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Presented by Quest Diagnostics

www.questdiagnostics.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Tue, 13 May 2025 17:25:53 +0000 stories@amazemedialabs.com (Jason Suomala, Dr. Jack Kain) https://the-results-are-in.simplecast.com/episodes/novel-psychoactive-substances-nps-a-dangerous-widespread-public-health-issue-BQoYYEi8 In this episode of Results are In by Quest Diagnostics, Dr. Jack Kain joins Jason Suomala to explain the threat of novel psychoactive substances and how Quest's updated testing panel helps providers identify what's being used and treat patients with more confidence. 

They break down what providers need to know about NPS classes like designer benzodiazepines, fentanyl analogs, synthetic cannabinoids, and more. With real-world case studies and clinical insights, the discussion highlights why traditional drug testing often misses these compounds—and how Quest’s updated NPS panel helps providers detect risk and guide treatment with greater accuracy.

The episode also explores how the evolving drug landscape, fueled by counterfeit pills and illicit drug mixing, is increasing overdose risks across the country. Whether you're a healthcare professional, toxicologist, or public health advocate, this conversation will help you better understand what’s really showing up in patients’ systems and what to do about it.

Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Presented by Quest Diagnostics

www.questdiagnostics.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Novel Psychoactive Substances (NPS): A Dangerous, Widespread Public Health Issue Jason Suomala, Dr. Jack Kain 00:26:21 Dr. Jack Kain discusses how novel psychoactive substances are complicating overdose treatment and how updated testing is helping clinicians respond faster. Dr. Jack Kain discusses how novel psychoactive substances are complicating overdose treatment and how updated testing is helping clinicians respond faster. false full 2 23904085-3778-4c9d-9b42-f251d13399ab Integrating Blood-Based Biomarkers for Alzheimer’s Risk Assessment In this episode of Results are In by Quest Diagnostics, Amanda Benson is joined by Dr. Michael Racke, Medical Director for Neurology at Quest Diagnostics, to discuss the groundbreaking role blood-based biomarkers play in assessing Alzheimer’s disease risk. Dr. Racke shares his expert insights on how these biomarkers are revolutionizing early risk detection and diagnosis, offering primary care physicians a proactive tool to identify Alzheimer’s before cognitive symptoms appear. From the evolution of Alzheimer's diagnostics to the practical application of plasma-based tests, Dr. Racke explains how integrating these tests into routine health visits can enable earlier interventions and better patient outcomes. He also discusses how blood-based biomarkers, in conjunction with digital cognitive assessments, are improving the sensitivity of Alzheimer’s screenings. This episode is a must-listen for anyone interested in the future of Alzheimer’s diagnostics and the power of early detection in cognitive health.

Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Presented by Quest Diagnostics
www.questdiagnostics.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 17 Jan 2025 05:00:00 +0000 stories@amazemedialabs.com (Amanda Benson, Dr. Michael Racke) https://the-results-are-in.simplecast.com/episodes/integrating-blood-based-biomarkers-for-alzheimers-risk-assessment-q8aOGHPt In this episode of Results are In by Quest Diagnostics, Amanda Benson is joined by Dr. Michael Racke, Medical Director for Neurology at Quest Diagnostics, to discuss the groundbreaking role blood-based biomarkers play in assessing Alzheimer’s disease risk. Dr. Racke shares his expert insights on how these biomarkers are revolutionizing early risk detection and diagnosis, offering primary care physicians a proactive tool to identify Alzheimer’s before cognitive symptoms appear. From the evolution of Alzheimer's diagnostics to the practical application of plasma-based tests, Dr. Racke explains how integrating these tests into routine health visits can enable earlier interventions and better patient outcomes. He also discusses how blood-based biomarkers, in conjunction with digital cognitive assessments, are improving the sensitivity of Alzheimer’s screenings. This episode is a must-listen for anyone interested in the future of Alzheimer’s diagnostics and the power of early detection in cognitive health.

Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Presented by Quest Diagnostics
www.questdiagnostics.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Integrating Blood-Based Biomarkers for Alzheimer’s Risk Assessment Amanda Benson, Dr. Michael Racke 00:26:31 Dr. Michael Racke discusses the role of blood-based biomarkers in early Alzheimer’s risk assessment and the impact on patient care through proactive diagnosis Dr. Michael Racke discusses the role of blood-based biomarkers in early Alzheimer’s risk assessment and the impact on patient care through proactive diagnosis false full 1 949ebcf6-59bf-4393-9faf-5b42be8d7b54 Welcome to The Results Are In Welcome to The Results Are In from Quest Diagnostics, where host Amanda Benson dives into the critical role of diagnostics in shaping the future of healthcare. Join industry-leading experts as they explore how comprehensive testing supports faster, more effective care and drives better patient outcomes across a wide range of clinical areas. From uncovering insights through Quest’s industry-leading diagnostic data to spotlighting the latest innovations in lab testing, this podcast is your go-to resource for staying informed on advancements in diagnostic medicine. Whether you’re looking to make testing work harder for your patients or simply want the inside track on the latest developments, The Results Are In is a must-listen. 

Follow Us

Presented by Quest Diagnostics

www.questdiagnostics.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Mon, 6 Jan 2025 21:05:36 +0000 stories@amazemedialabs.com (Amanda Benson) https://the-results-are-in.simplecast.com/episodes/welcome-to-the-results-are-in-LVJhZIL0 Welcome to The Results Are In from Quest Diagnostics, where host Amanda Benson dives into the critical role of diagnostics in shaping the future of healthcare. Join industry-leading experts as they explore how comprehensive testing supports faster, more effective care and drives better patient outcomes across a wide range of clinical areas. From uncovering insights through Quest’s industry-leading diagnostic data to spotlighting the latest innovations in lab testing, this podcast is your go-to resource for staying informed on advancements in diagnostic medicine. Whether you’re looking to make testing work harder for your patients or simply want the inside track on the latest developments, The Results Are In is a must-listen. 

Follow Us

Presented by Quest Diagnostics

www.questdiagnostics.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Welcome to The Results Are In Amanda Benson 00:01:16 Explore innovations in diagnostic testing and insights from industry leaders on The Results Are In from Quest Diagnostics. Explore innovations in diagnostic testing and insights from industry leaders on The Results Are In from Quest Diagnostics. false trailer